Innovation through Collaboration
Throughout the past year, we have continued to work relentlessly for families across the nation and around the globe: pioneering breakthroughs, finding better answers and providing compassionate clinical care. We do this in collaboration with you, our colleagues near and far, to change the outcome for patients. Together, we’re building a world where every child can live their best possible life.
![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/article/key_visual/458/Meettheteam__2_.jpg)
Meet Our Team
![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/staff/image/4086/Perentesis.jpg)
See Info
![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/staff/image/4086/Perentesis.jpg)
John Perentesis, MD, FAAP
Director, Division of Oncology and Cancer Programs; Co-Executive Director, Cancer and Blood Diseases Institute; Deb Kleisinger Endowed Chair 513-636-8241 john.perentesis@cchmc.org![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/article/key_visual/459/700_by_350..png)
After the World’s First FLASH Proton Therapy Clinical Trial Shows Promise, a Second Trial is Underway
![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/staff/image/4087/CBDI_rk0796.png)
See Info
![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/staff/image/4087/CBDI_rk0796.png)
YunZu Michele Wang, MD
Member, Division of Bone Marrow Transplantation and Immune Deficiency yunzu.wang@cchmc.org![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/article/key_visual/460/700_by_503.png)
Novel Natural Killer Cell Therapy is the Focus of a New Clinical Study for Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/staff/image/4088/myers-kasiani.jpg)
See Info
![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/staff/image/4088/myers-kasiani.jpg)
Kasiani Myers, MD
Member, Division of Bone Marrow Transplantation and Immune Deficiency kasiani.myers@cchmc.org![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/article/key_visual/461/700_by_472...png)
Novel Cell Therapy Strategy Achieves Telomere Elongation in Clinical Trial, a Potential Breakthrough in the Treatment of Telomere Biology Disorders
![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/staff/image/4089/20230519.png)
See Info
![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/staff/image/4089/20230519.png)
Michael Grimley, MD
Medical Director, Division of Bone Marrow Transplantation and Immune Deficiency michael.grimley@cchmc.org![](https://slmktg-cchmc-accomplishments.s3.amazonaws.com/uploads/article/key_visual/462/700_by_350..png)
Cincinnati Children’s Infuses Its First Two Patients with Newly Approved Beta Thalassemia Gene Therapy